Anglo-French Drugs & Industries Ltd Unlisted Shares
Industry: Manufacturing | Sector: Pharma
Depository: NSDL, CDSL
₹ 3,600.00
Anglo-French Drugs & Industries Ltd Unlisted Shares
Industry: Manufacturing | Sector: Pharma | Depository: NSDL, CDSL
₹ 3,600.00
Key Indicators
| Key Indicators | 2025 |
|---|---|
| Current Share Price | 3,600.00 |
| Face Value | Share | 10.00 |
| Book Value | Share | 1,134.55 |
| Price To Earning (PE) | 58.06 |
| Price | Sales | 3.36 |
| Price | Book | 3.17 |
| Outstanding Shares (Crores) | 0.11 |
| Market Cap (Rs. Crores) | 396.00 |
| Debt | Equity | 0.50 |
| Dividend | Share | 1.50 |
| Dividend % (On Current Market Price) | 0.2% |
| Return on Total Assets | 3.7% |
| Return on Equity | 5.7% |
| Return on Working Capital | 7.2% |
* Ratio is calculated based on latest financial & current share price.
About The Company
Anglo-French Drugs & Industries Limited (AFDIL) operates as a pharmaceutical company. The Company manufactures and processes vitamins, anti-epileptics, anti-oxidants, sleep inducing agents, cold and cough preparations, protein food supplements, digestive enzymes, and calcium supplements. AFDIL serves clients worldwide. Quality At AFDIL, Quality is of foremost concern. In nearly 100 years of operations, we have continuously remained one of India’s most trustworthy manufacturers. Our commitment to quality is managed by current and validated technology, the best resources, effective cGMP, efficient and trained personnel, excellent production design
Pricing Trend
Financial Summary
Revenue Growth %
EBITDA Margin %
NET Margin %
Profit & Loss Summary
(All Amount in ₹ Crores)
| PROFIT & LOSS | 2025 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 118.0 | 166.1 | 154.8 | 131.7 | 129.8 | 112.4 |
| Expense | 105.0 | 156.7 | 137.4 | 117.8 | 122.2 | 119.2 |
| EBITDA | 13.0 | 9.4 | 17.4 | 13.9 | 7.6 | -6.8 |
| Other Cost | 5.1 | 7.2 | 7.8 | 10.3 | 8.5 | 6.1 |
| Profit Before Taxes | 7.9 | 2.2 | 9.6 | 3.6 | -0.9 | -12.9 |
| Tax Expense | 0.7 | 0.4 | 2.1 | 0.6 | 0.0 | -1.7 |
| Profit after Taxes | 7.2 | 1.9 | 7.5 | 3.1 | -0.9 | -11.2 |
| Other Income | Exp. | -0.1 | 0.0 | -0.3 | -0.2 | 0.4 | 0.2 |
| Income (Net Of Taxes) | 7.1 | 1.9 | 7.5 | 3.1 | -0.8 | -11.2 |
| Outstanding Share | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 |
| Earning per Share (Rs | Share) | 62 | 16.0 | 5.8 | 2.7 | -0.7 | -9.7 |
| Revenue Growth % | -29% | 7.3% | 17.5% | 1.5% | 15.5% | - |
| EBITDA Margin % | 11% | 5.7% | 11.2% | 10.6% | 5.9% | -6% |
| Net Margin % | 6% | 1.1% | 4.8% | 2.4% | -0.6% | -10% |
| Earning per Share Growth % | 287.5% | 175.9% | 114.8% | -485.7% | -92.8% | - |
Balance Sheet
(All Amount in ₹ Crores)
| Balance Sheet | 2025 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Cash & Cash Equivalent | 0.2 | 2.1 | 1.2 | 0.6 | 0.9 | 2.7 |
| Non Current Asset | 31.7 | 19.2 | 14.2 | 16.6 | 16.2 | 17.2 |
| Current Asset | 160.5 | 75.8 | 79.4 | 75.9 | 76.7 | 85.9 |
| Total Asset | 192.4 | 97.1 | 94.8 | 93.1 | 93.7 | 105.8 |
| Equity Share Capital | 1.1 | 1.3 | 1.3 | 1.2 | 1.2 | 1.2 |
| Reserves | 123.7 | 17.6 | 14.8 | 5.4 | 2.8 | 3.5 |
| Total Equity | 124.8 | 18.9 | 16.1 | 6.5 | 4.0 | 4.7 |
| Non Current Liability | 11.3 | 30.2 | 21.0 | 13.5 | 11.5 | 12.5 |
| Current Liability | 56.4 | 48.0 | 57.7 | 73.0 | 78.3 | 88.7 |
| Total Liabilities | 67.6 | 101.2 | 78.7 | 86.6 | 89.8 | 101.1 |
| Total Equity & Liability | 192.4 | 97.1 | 94.8 | 93.1 | 93.7 | 105.8 |
Cash Flow Summary
(All Amount in ₹ Crores)
| CASH FLOW SUMMARY | 2025 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Activity | 1.9 | 13.7 | 4.5 | 15.1 | 7.1 | -13.7 |
| Investing Activity | 44.7 | -9.1 | -0.8 | -2.7 | -0.6 | -0.5 |
| Financing Activity | -46.5 | -4.8 | -3.3 | -12.4 | -8.3 | 16.1 |
| Net Cash Flow | 0.1 | -0.1 | 0.4 | 0.0 | -1.8 | 1.8 |
Share Holding
Registered Address
ISIN: INE570E01016
PAN: AAACA9756E
No. 41, 3rd Cross, 5th Block, Rajajinagar, Bengaluru – 560 010, Karnataka , India.
Management
Mr. Abhay Kanoria
chairman & managing director
Mr. Harshwardhan Murarka
chief financial officer
Mrs. Deepa Ramachandran
company secretary
Download Financial Result
Top Unlisted companies
About Anglo-French Drugs & Industries Ltd Unlisted Shares
AFDIL is a pharmaceutical company based in Bangalore and Mumbai. The first company to produce a single vitamin injection and B-complex combination. We are one of the leading platforms for buying and selling of Anglo-French drugs and Ind Ltd. shares.
...Frequently Asked Questions
How to buy unlisted shares of Anglo French Drugs and Ind. Ltd?
How to Sell unlisted shares of Anglo French Drugs and Ind. Ltd?
What is the lock-in period of Anglo French Drugs and Ind. Ltd unlisted shares?
What is the minimum ticket size for investment in Anglo French Drugs and Ind. Ltd unlisted shares?
Is it legal to buy unlisted shares of Anglo French Drugs and Ind. Ltd in India?
Is Short-term capital gain tax applicable on Anglo French Drugs and Ind. Ltd unlisted shares?
Is there any Long-term capital gain tax to be paid on Anglo French Drugs and Ind. Ltd unlisted shares?
Applicability of Taxes on Anglo French Drugs and Ind. Ltd unlisted shares once it is listed?
How to check the credit or transfers of Anglo French Drugs and Ind. Ltd unlisted shares?
What is the documentation requirement for dealing in unlisted shares?
What are expected returns on unlisted shares of Anglo French Drugs and Ind. Ltd shares?
